Literature DB >> 21325059

In vivo demonstration that alpha-synuclein oligomers are toxic.

Beate Winner1, Roberto Jappelli, Samir K Maji, Paula A Desplats, Leah Boyer, Stefan Aigner, Claudia Hetzer, Thomas Loher, Marçal Vilar, Silvia Campioni, Christos Tzitzilonis, Alice Soragni, Sebastian Jessberger, Helena Mira, Antonella Consiglio, Emiley Pham, Eliezer Masliah, Fred H Gage, Roland Riek.   

Abstract

The aggregation of proteins into oligomers and amyloid fibrils is characteristic of several neurodegenerative diseases, including Parkinson disease (PD). In PD, the process of aggregation of α-synuclein (α-syn) from monomers, via oligomeric intermediates, into amyloid fibrils is considered the disease-causative toxic mechanism. We developed α-syn mutants that promote oligomer or fibril formation and tested the toxicity of these mutants by using a rat lentivirus system to investigate loss of dopaminergic neurons in the substantia nigra. The most severe dopaminergic loss in the substantia nigra is observed in animals with the α-syn variants that form oligomers (i.e., E57K and E35K), whereas the α-syn variants that form fibrils very quickly are less toxic. We show that α-syn oligomers are toxic in vivo and that α-syn oligomers might interact with and potentially disrupt membranes.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21325059      PMCID: PMC3053976          DOI: 10.1073/pnas.1100976108

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

Review 1.  Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders.

Authors:  Byron Caughey; Peter T Lansbury
Journal:  Annu Rev Neurosci       Date:  2003-04-09       Impact factor: 12.449

2.  A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR.

Authors:  Aneta T Petkova; Yoshitaka Ishii; John J Balbach; Oleg N Antzutkin; Richard D Leapman; Frank Delaglio; Robert Tycko
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-12       Impact factor: 11.205

3.  Structural organization of alpha-synuclein fibrils studied by site-directed spin labeling.

Authors:  Ani Der-Sarkissian; Christine C Jao; Jeannie Chen; Ralf Langen
Journal:  J Biol Chem       Date:  2003-06-18       Impact factor: 5.157

4.  alpha-Synuclein locus triplication causes Parkinson's disease.

Authors:  A B Singleton; M Farrer; J Johnson; A Singleton; S Hague; J Kachergus; M Hulihan; T Peuralinna; A Dutra; R Nussbaum; S Lincoln; A Crawley; M Hanson; D Maraganore; C Adler; M R Cookson; M Muenter; M Baptista; D Miller; J Blancato; J Hardy; K Gwinn-Hardy
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

5.  Effects of Parkinson's disease-linked mutations on the structure of lipid-associated alpha-synuclein.

Authors:  Robert Bussell; David Eliezer
Journal:  Biochemistry       Date:  2004-04-27       Impact factor: 3.162

6.  Correlation of structural elements and infectivity of the HET-s prion.

Authors:  Christiane Ritter; Marie-Lise Maddelein; Ansgar B Siemer; Thorsten Lührs; Matthias Ernst; Beat H Meier; Sven J Saupe; Roland Riek
Journal:  Nature       Date:  2005-06-09       Impact factor: 49.962

7.  The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease.

Authors:  Ronit Sharon; Ifat Bar-Joseph; Matthew P Frosch; Dominic M Walsh; James A Hamilton; Dennis J Selkoe
Journal:  Neuron       Date:  2003-02-20       Impact factor: 17.173

8.  Ageing and Parkinson's disease: substantia nigra regional selectivity.

Authors:  J M Fearnley; A J Lees
Journal:  Brain       Date:  1991-10       Impact factor: 13.501

9.  Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease.

Authors:  K A Conway; J D Harper; P T Lansbury
Journal:  Nat Med       Date:  1998-11       Impact factor: 53.440

10.  The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia.

Authors:  Juan J Zarranz; Javier Alegre; Juan C Gómez-Esteban; Elena Lezcano; Raquel Ros; Israel Ampuero; Lídice Vidal; Janet Hoenicka; Olga Rodriguez; Begoña Atarés; Verónica Llorens; Estrella Gomez Tortosa; Teodoro del Ser; David G Muñoz; Justo G de Yebenes
Journal:  Ann Neurol       Date:  2004-02       Impact factor: 10.422

View more
  530 in total

1.  Mutual exacerbation of peroxisome proliferator-activated receptor γ coactivator 1α deregulation and α-synuclein oligomerization.

Authors:  Judith Eschbach; Björn von Einem; Kathrin Müller; Hanna Bayer; Annika Scheffold; Bradley E Morrison; K Lenhard Rudolph; Dietmar R Thal; Anke Witting; Patrick Weydt; Markus Otto; Michael Fauler; Birgit Liss; Pamela J McLean; Albert R La Spada; Albert C Ludolph; Jochen H Weishaupt; Karin M Danzer
Journal:  Ann Neurol       Date:  2014-12-19       Impact factor: 10.422

Review 2.  Protein degradation pathways in Parkinson's disease: curse or blessing.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  Acta Neuropathol       Date:  2012-06-29       Impact factor: 17.088

3.  Aggregate clearance of α-synuclein in Saccharomyces cerevisiae depends more on autophagosome and vacuole function than on the proteasome.

Authors:  Doris Petroi; Blagovesta Popova; Naimeh Taheri-Talesh; Stefan Irniger; Hedieh Shahpasandzadeh; Markus Zweckstetter; Tiago F Outeiro; Gerhard H Braus
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

Review 4.  Immunotherapy for neurodegenerative diseases: focus on α-synucleinopathies.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Pharmacol Ther       Date:  2013-02-04       Impact factor: 12.310

Review 5.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

6.  Isoindole Linkages Provide a Pathway for DOPAL-Mediated Cross-Linking of α-Synuclein.

Authors:  Jonathan W Werner-Allen; Sarah Monti; Jenna F DuMond; Rodney L Levine; Ad Bax
Journal:  Biochemistry       Date:  2018-02-15       Impact factor: 3.162

7.  ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.

Authors:  Valentín Cóppola-Segovia; Clarissa Cavarsan; Flavia G Maia; Anete C Ferraz; Lia S Nakao; Marcelo Ms Lima; Silvio M Zanata
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

8.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

9.  Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.

Authors:  Mari H Savolainen; Katrina Albert; Mikko Airavaara; Timo T Myöhänen
Journal:  Exp Brain Res       Date:  2017-04-24       Impact factor: 1.972

10.  X-ray Crystallographic Structures of Oligomers of Peptides Derived from β2-Microglobulin.

Authors:  Ryan K Spencer; Adam G Kreutzer; Patrick J Salveson; Hao Li; James S Nowick
Journal:  J Am Chem Soc       Date:  2015-05-12       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.